Cargando…
Glucocorticoid-Induced Hyperglycemia Including Dexamethasone-Associated Hyperglycemia in COVID-19 Infection: A Systematic Review
OBJECTIVE: Optimal glucocorticoid-induced hyperglycemia (GCIH) management is unclear. The COVID-19 pandemic has made this issue more prominent because dexamethasone became the standard of care in patients needing respiratory support. This systematic review aimed to describe the management of GCIH an...
Autores principales: | Brooks, Danielle, Schulman-Rosenbaum, Rifka, Griff, Megan, Lester, Janice, Low Wang, Cecilia C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AACE. Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354392/ https://www.ncbi.nlm.nih.gov/pubmed/35940469 http://dx.doi.org/10.1016/j.eprac.2022.07.014 |
Ejemplares similares
-
Management of Glucocorticoid-Induced Hyperglycemia
por: Shah, Parag, et al.
Publicado: (2022) -
Dexamethasone use and insulin requirements in coronovirus-19 (COVID-19) infection stratified by Hemoglobin A1c
por: Gordon, Caitlyn, et al.
Publicado: (2023) -
Abstract #1153925: Dexamethasone Use and Insulin Requirements in Coronavirus Disease-19 (COVID-19) Infection
por: Barsoum, Barbara, et al.
Publicado: (2022) -
Effect of insulin plant leaves on dexamethasone-induced hyperglycemia
por: Ghaisas, Saket M.
Publicado: (2011) -
Hyperglycemia, glucocorticoid therapy, and outcome of COVID-19
por: Morieri, Mario Luca, et al.
Publicado: (2020)